Accumulation of β-amyloid (Aβ) protein within the brain is a neuropathological hallmark of Alzheimer’s disease (AD). One strategy to facilitate Aβ clearance from the brain is to promote Aβ catabolism. Matrix metalloproteinase-9 (MMP-9), a member of the family of Zn+2-containing endoproteases, known to be expressed and secreted by astrocytes, is capable of degrading Aβ. Histamine, a major aminergic brain neurotransmitter, stimulates the production of MMP-9 in keratinocytes through the histamine H1 receptor (H1R). In the present study, we show that histamine evokes a concentration- and calcium-dependent release of MMP-9 from human astrocytic U373 cells and primary cultures of human and rat astrocytes through the H1R subtype. Activation of H1R on astrocytes elevated intracellular levels of Ca2+ that was accompanied by time-dependent increases in MAP kinase p44/p42 and PKC. In-cell western blots revealed dose-dependent increases in both enzymes, confirming involvement of these signal transduction pathways. We next investigated the extent of recombinant human MMP-9 (rhMMP-9) proteolytic activity on soluble oligomeric Aβ (soAβ). Mass spectrometry demonstrated time-dependent cleavage of soAβ (20 μM), but not another amyloidogenic protein amylin, upon incubation with rhMMP-9 (100 nM) at 1, 4 and 17 h. Furthermore, Western blots showed a shift in soAβ equilibrium toward lower order, less toxic monomeric species. In conclusion, both MAPK p44/p42 and PKC pathways appear to be involved in histamine-upregulated MMP-9 release via H1Rs in astrocytes. Furthermore, MMP-9 appears to cleave soAβ into less toxic monomeric species. Given the key role of histamine in MMP-9 release, this neurotransmitter may serve as a potential therapeutic target for AD.
This is a preview of subscription content, log in to check access.
We thank the Pulmonary Research Group at the University of Alberta for access to ICW instrumentation and technical assistance with experiments utilizing this technique. We also thank Dr. K. Ballanyi for assistance with calcium imaging experiments. This research was supported by grants from the University Hospital Foundation (FoMD/UHF Medical Grants competition) and Canadian Institutes of Health Research (CIHR MOP 93601 to JHJ).
Supplementary Fig. 1 Gelatin zymogram showing histamine-induced upregulation of Pro-MMP-9 production was not blocked in a concentration-dependent manner following 24 h pre-incubation with H2R (Ranitidine HCl) and H3R (Clobenpropit HCl) antagonists (2.5–100 µM dose range) (EPS 4463 kb)
Arias-Montano JA, Berger V, Young JM (1994) Calcium-dependence of histamine- and carbachol-induced inositol phosphate formation in human U373 MG astrocytoma cells: comparison with HeLa cells and brain slices. Br J Pharmacol 111:598–608CrossRefPubMedPubMedCentralGoogle Scholar
Asahina M, Yoshiyama Y, Hattori T (2001) Expression of matrix metalloproteinase-9 and urinary-type plasminogen activator in Alzheimer’s disease brain. Clin Neuropathol 20:60–63PubMedGoogle Scholar
Backstrom JR, Lim GP, Cullen MJ, Tokes ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16:7910–7919PubMedGoogle Scholar
Bakker RA, Timmerman H, Leurs R (2002) Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 17:27–64PubMedGoogle Scholar
Berman NE et al (1999) Microglial activation and neurological symptoms in the SIV model of NeuroAIDS: association of MHC-II and MMP-9 expression with behavioral deficits and evoked potential changes. Neurobiol Dis 6:486–498. doi:10.1006/nbdi.1999.0261CrossRefPubMedGoogle Scholar
Carman-Krzan M, Vige X, Wise BC (1991) Regulation by interleukin-1 of nerve growth factor secretion and nerve growth factor mRNA expression in rat primary astroglial cultures. J Neurochem 56:636–643CrossRefPubMedGoogle Scholar
Deb S, Gottschall PE (1996) Increased production of matrix metalloproteinases in enriched astrocyte and mixed hippocampal cultures treated with beta-amyloid peptides. J Neurochem 66:1641–1647CrossRefPubMedGoogle Scholar
Gschwandtner M, Purwar R, Wittmann M, Baumer W, Kietzmann M, Werfel T, Gutzmer R (2008) Histamine upregulates keratinocyte MMP-9 production via the histamine H1 receptor. J Invest Dermatol 128:2783–2791. doi:10.1038/jid.2008.153CrossRefPubMedGoogle Scholar
Komatsu K, Nakanishi Y, Nemoto N, Hori T, Sawada T, Kobayashi M (2004) Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathol 21:105–112CrossRefPubMedGoogle Scholar
Leissring MA (2006) Proteolytic degradation of the amyloid beta-protein: the forgotten side of Alzheimer’s disease. Curr Alzheimer Res 3:431–435CrossRefPubMedGoogle Scholar
Li SF, Wu MN, Wang XH, Yuan L, Yang D, Qi JS (2011) Requirement of alpha7 nicotinic acetylcholine receptors for amyloid beta protein-induced depression of hippocampal long-term potentiation in CA1 region of rats in vivo. Synapse 65:1136–1143. doi:10.1002/syn.20951CrossRefPubMedGoogle Scholar
Lipnik-Stanglj M, Carman-Krzan M (2000) The effects of histamine and interleukin-6 on NGF release from cortical astrocytes in primary culture. Pflugers Arch 440:R99–R100PubMedGoogle Scholar
Matsubara M, Tamura T, Ohmori K, Hasegawa K (2005) Histamine H1 receptor antagonist blocks histamine-induced proinflammatory cytokine production through inhibition of Ca2+-dependent protein kinase C, Raf/MEK/ERK and IKK/I kappa B/NF-kappa B signal cascades. Biochem Pharmacol 69:433–449. doi:10.1016/j.bcp.2004.10.006CrossRefPubMedGoogle Scholar
Ruangkittisakul A, Schwarzacher SW, Secchia L, Poon BY, Ma Y, Funk GD, Ballanyi K (2006) High sensitivity to neuromodulator-activated signaling pathways at physiological [K+] of confocally imaged respiratory center neurons in on-line-calibrated newborn rat brainstem slices. J Neurosci 26:11870–11880. doi:10.1523/JNEUROSCI.3357-06.2006CrossRefPubMedGoogle Scholar
Saido TC (1998) Alzheimer’s disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging 19:S69–S75CrossRefPubMedGoogle Scholar
Saito T, Takaki Y, Iwata N, Trojanowski J, Saido TC (2003) Alzheimer’s disease, neuropeptides, neuropeptidase, and amyloid-beta peptide metabolism. Sci Aging Knowledge Environ 2003:PE1CrossRefPubMedGoogle Scholar
Selkoe DJ (2000) Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 924:17–25CrossRefPubMedGoogle Scholar
Vehmas AK, Kawas CH, Stewart WF, Troncoso JC (2003) Immune reactive cells in senile plaques and cognitive decline in Alzheimer’s disease. Neurobiol Aging 24:321–331CrossRefPubMedGoogle Scholar
Wegiel J, Wang KC, Tarnawski M, Lach B (2000) Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol 100:356–364CrossRefPubMedGoogle Scholar
Yang BC, Chen RF, Chio CC, Chang WC, Lin MT, Lin SJ (1998) Effects of insulin on protein phosphorylation and protein kinase C activity in human malignant gliomas. Proc Natl Sci Counc Repub China B 22:22–30PubMedGoogle Scholar